Test directory: JAK2, V617F Mut. w/Reflex Exon 12

Ordering Code 6613
Test Name JAK2, V617F Mut. w/Reflex Exon 12
Alias JAK2 (V617F) Mutation by ddPCR, Qualitative with
Reflex to JAK2 Exon 12 Mutation Analysis by PCR
Preferred Specimen Whole Blood
Preferred Container EDTA, K2 (Lavender)
Optimum Volume 5 mL
Collection Instructions Perform collection on Monday through Thursday only.
Transport Requirements Oahu: Refrigerated
Airline: Refrigerated
Specimen Stability Ambient: Not Stable
Refrigerated: 7 Days
Frozen: Not Stable
Rejection Criteria Plasma, Serum, FFPE tissue blocks/slides, or fresh or frozen tissue, Specimens collected in anticoagulants other than
EDTA, Clotted or grossly hemolyzed specimens
Avail. Stat NO
Analytic Time 14-21 Days
Methodology Droplet Digital Polymerase Chain Reaction/Polymerase
Chain Reaction
Reference Lab  ARUP Laboratories

Reference range(s)

The reference ranges listed below are valid on this date of June 1, 2025.
Component Age Male Norm Male Critical Low Male Critical High Female Norm Female Critical High Female Critical Low Units Add'l info
JAK2 Qual, Source ALL See report.
JAK2 Gene, V617F Mutation, Qual. ALL

INTERPRETIVE...
INTERPRETIVE INFORMATION
This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms

Methodology: DNA from whole blood or bone marrow specimens is amplified in an allele-specific droplet digital PCR (ddPCR) multiplex reaction targeting the JAK2 c.1849G>T single nucleotide mutation encoding the V617F mutation. The limit of detection for this assay is 0.5 percent mutated alleles

Limitations: Variants in genes other than JAK2 are not detected. JAK2 variants other than V617F (c.1849G>T) are not reported. Samples with JAK2
V617F mutations below the limit of detection are not reported

Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy

This test was developed and its performance characteristics determined by ARUP Laboratories
It has not been cleared or approved by the U.S
Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes

See report.
Note1

Note1:


INTERPRETIVE INFORMATION
This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms

Methodology: DNA from whole blood or bone marrow specimens is amplified in an allele-specific droplet digital PCR (ddPCR) multiplex reaction targeting the JAK2 c.1849G>T single nucleotide mutation encoding the V617F mutation. The limit of detection for this assay is 0.5 percent mutated alleles

Limitations: Variants in genes other than JAK2 are not detected. JAK2 variants other than V617F (c.1849G>T) are not reported. Samples with JAK2
V617F mutations below the limit of detection are not reported

Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy

This test was developed and its performance characteristics determined by ARUP Laboratories
It has not been cleared or approved by the U.S
Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes

See report..